Cargando…
XPG is a novel biomarker of clinical outcome in advanced non-small-cell lung cancer
Objective: Polymorphisms in XPG were considered to contribute to the clinical outcome of patients receiving platinum drug chemotherapy. We investigated the impact of several potential SNPs of XPG on the efficacy of platinum-based chemotherapy in NSCLC patients. Methods: A total of 433 patients were...
Autores principales: | Yuli, Yi, Zhe, Sun, Xia, WANG, Siqing, LI, Zhenxuan, WU, Yu-hua, ZHU, Bing, Sun, Jun-wei, Cui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Professional Medical Publicaitons
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3809298/ https://www.ncbi.nlm.nih.gov/pubmed/24353624 |
Ejemplares similares
-
XPG: a multitasking genome caretaker
por: Muniesa-Vargas, Alba, et al.
Publicado: (2022) -
XPG rs2296147 T>C polymorphism predicted clinical outcome in colorectal cancer
por: Wang, Fang, et al.
Publicado: (2016) -
Expression of XPG Protein in the Development, Progression and Prognosis of Gastric Cancer
por: Deng, Na, et al.
Publicado: (2014) -
Domain swapping between FEN-1 and XPG defines regions in XPG that mediate nucleotide excision repair activity and substrate specificity
por: Hohl, Marcel, et al.
Publicado: (2007) -
XPG gene polymorphisms and cancer susceptibility: evidence from 47 studies
por: Huang, Jiawen, et al.
Publicado: (2017)